At first glance, it seems like a rough time for venture capital, especially in the healthcare industry. Overall, venture investments in 2022 were down 35% from 2021, according to CB Insights, with digital health investments down over 50%. Biopharma investment beat the trend a little bit, according to Evaluate Vantage, down only 23% from the year before.
Image: Dimension founders Zavian Dar, Adam Goulburn and Nan LiDIMENSION
{iframe}https://www.forbes.com/sites/alexknapp/2023/01/25/dimension-350-million-biotech-compute-ai-venture-fund/?sh=44ef61fd4fff{/iframe}